Case Report: Efgartigimod as an additional therapy for MOG antibody-associated disease overlapping GFAP-IgG

病例报告:Efgartigimod 作为 MOG 抗体相关疾病(与 GFAP-IgG 重叠)的辅助治疗

阅读:2

Abstract

INTRODUCTION: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy have received increasing attention in recent years. However, the coexistence of anti-MOG and anti-GFAP antibodies has rarely been reported. CASE: A 53-year-old man presented with a headache, slow reaction, nonsense talk, unsteady walking without diplopia or decreased vision. Lumbar puncture revealed the presence of anti-MOG and anti-GFAP antibodies in the cerebrospinal fluid. Magnetic resonance imaging revealed multiple high signal intensities in the white matter. The patient was diagnosed with MOGAD syndrome with overlapping GFAP-IgG. Treatment comprised high-dose methylprednisolone and efgartigimod therapy, followed by gradual tapering of oral prednisolone and the addition of an immunosuppressant, leading to symptomatic improvement and sustained remission. CONCLUSION: We report a case of MOGAD-overlapping GFAP IgG treated with combination therapy of steroids and efgartigimod. This case enhances our understanding of the clinical manifestations of overlapping syndromes and expands the treatment options for this disorder.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。